Fascinating and very timely for me. I was privileged to sit through a talk by the head of cancer immunotherapy at our institution where he was explaining the pa

Fascinating and very timely for me. I was privileged to sit through a talk by the head of cancer immunotherapy at our institution where he was explaining the past, present and future journey of cancer immunotherapy research and this exact topic of mouse model applicability to human subjects came up. His TLDR on this was that differences are likely due to - 1. Controlled lines of mice bred specifically to minimize confounding during pre-clinical studies 2. Immune response activation pathways differing from "in the wild" situations for actual subjects 3. The immense diversity of gut microbiota, their temporal and inherited gene signatures and impacts on drug metabolism which are incredibly hard to control for in experiments Very nice to see an approachable post out there outlining a lot of these issues.